you are here: Home News Generics

Generics

Fresh Trump tariffs, what is at stake for Indian pharma, and the playbook to survive
IPA rejects Ohio University study linking higher adverse events to made in India generics
Indian drugmakers weigh portfolio rejig, manufacturing realignment to survive US tariffs
Hetero finds positive results from Molnupiravir third phase trials
Veterans Unpacked | D.S. Brar: "Your network is your net worth, and your credibility is your currency"
Corporate Corridor | Pfizer’s Upjohn and Mylan combining forces holds lessons for Indian pharma majors
Dr Reddy’s Suboxone launch: Why investors shrugged it off
Why Scott Gottlieb, the new US FDA chief, could be good news for Indian drug makers
Pharma stocks gain post Clinton's loss: Sun, Dr Reddy‘s up 5%
EY Passion to Win: Here's the success story of the Lupin duo
US-led trade deal will raise prices: Indian drug industry
Lupin to beef up branded portfolio through alliances
Lupin falls 6%, analysts revise target post weak Q4 results
3 reasons why BofA-Merrill is still hot on Cipla
Lupin scouts for acquisitions in US
Why action is unlikely in US generics pricing probe
US drug patent expiries to benefit Indian pharma industry
USFDA nod will aid Ranbaxy's sentiment, not revenue: Expert
Swedish drugmaker Meda says not in sale talks
Dr Reddy's Q4 cons net jumps 67% to Rs 571 cr
Ranbaxy misses estimates; Q1 net sinks 90%
Glenmark: Environment challenging, see 20% growth in FY14
Glenmark settles patent litigation with Janssen Pharma
Glenmark, Aurobindo get US nod for asthma treatment drug
Growth in quarter driven by generics: Lupin

English

Markets

News

Personal Finance

Mutual Funds

Commodities

Media

Invest Now

Specials

Generics

Fresh Trump tariffs, what is at stake for Indian pharma, and the playbook to survive

IPA rejects Ohio University study linking higher adverse events to made in India generics

Indian drugmakers weigh portfolio rejig, manufacturing realignment to survive US tariffs

Hetero finds positive results from Molnupiravir third phase trials

Veterans Unpacked | D.S. Brar: "Your network is your net worth, and your credibility is your currency"

Corporate Corridor | Pfizer’s Upjohn and Mylan combining forces holds lessons for Indian pharma majors

Dr Reddy’s Suboxone launch: Why investors shrugged it off

Why Scott Gottlieb, the new US FDA chief, could be good news for Indian drug makers

Pharma stocks gain post Clinton's loss: Sun, Dr Reddy‘s up 5%

EY Passion to Win: Here's the success story of the Lupin duo

US-led trade deal will raise prices: Indian drug industry

Lupin to beef up branded portfolio through alliances

Lupin falls 6%, analysts revise target post weak Q4 results

3 reasons why BofA-Merrill is still hot on Cipla

Lupin scouts for acquisitions in US

Why action is unlikely in US generics pricing probe

US drug patent expiries to benefit Indian pharma industry

USFDA nod will aid Ranbaxy's sentiment, not revenue: Expert

Swedish drugmaker Meda says not in sale talks

Dr Reddy's Q4 cons net jumps 67% to Rs 571 cr

Ranbaxy misses estimates; Q1 net sinks 90%

Glenmark: Environment challenging, see 20% growth in FY14

Glenmark settles patent litigation with Janssen Pharma

Glenmark, Aurobindo get US nod for asthma treatment drug

Growth in quarter driven by generics: Lupin